Thomas Conner, MD
Obstetrics · Salt Lake City, UTNPI 1780619023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 31.9% of the total.
Across 138 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$825
- Boehringer Ingelheim$191
- Lilly USA, LLC$191
- Pfizer$182
- GSK$157
- Amgen$107
- plus $931 from 28 others
What the payments were for
- Food & beverage$2,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $825 |
| Boehringer Ingelheim | 10 | $191 |
| Lilly USA, LLC | 12 | $191 |
| Pfizer | 7 | $182 |
| GSK | 10 | $157 |
| Amgen(2 entities) | 6 | $107 |
| Astellas Pharma US Inc | 4 | $74 |
| Dynavax Technologies Corporation | 5 | $73 |
| Novartis | 4 | $65 |
| Gilead | 3 | $65 |
| Medtronic | 3 | $55 |
| Corium, LLC | 3 | $51 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Merck | 3 | $41 |
| Quidel Corporation | 1 | $41 |
| Abbott | 2 | $41 |
| Seqirus USA Inc | 3 | $39 |
| AstraZeneca | 3 | $37 |
| Boston Scientific | 2 | $36 |
| Corcept Therapeutics | 2 | $29 |
| Novo Nordisk | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Treace Medical Concepts, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Sonex Health, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Organon | 1 | $11 |
How this compares
Too few obstetrics providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 15 | $75,180 |
| MounjaroTirzepatide | 34 | $36,193 |
| JardianceEmpagliflozin | 18 | $24,950 |
| OzempicSemaglutide | 26 | $22,535 |
| EliquisApixaban | 21 | $19,225 |
| XareltoRivaroxaban | 13 | $16,342 |
| FarxigaDapagliflozin Propanediol | 15 | $12,249 |
| MyrbetriqMirabegron | 11 | $10,802 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $10,459 |
| BelsomraSuvorexant | 19 | $8,498 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 117 | $7,272 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 145 | $4,337 |
| Oxycodone Hcl | 138 | $4,105 |
| Morphine Sulfate ErMorphine Sulfate | 99 | $3,699 |
| Fentanyl | 15 | $3,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $191 | $36,19334 claims |
| Boehringer IngelheimJardiance | $191 | $24,95018 claims |
| Novo NordiskOzempic | $27 | $22,53526 claims |
| PfizerEliquis | $182 | $19,22521 claims |
| MerckJanumet Xr, Belsomra | $41 | $18,95730 claims |
| Johnson & JohnsonXarelto | $26 | $16,34213 claims |
| AstraZenecaFarxiga | $37 | $12,24915 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $10,80211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obstetrics providers in Utahon file to place this against a meaningful peer group, so we don't.
Other obstetrics in Salt Lake City
- James PetersonSalt Lake City$11K
- Shane ChristensenSalt Lake City$6K
- Gayle StewartSalt Lake City$5K
- Natalie LoewenSalt Lake City$46
- Cynthia JonesSalt Lake City$18
- Layne SmithDraper$8K
- Cameron LeavittSt George$3K
- Robert LaterSandy$2K
- Chad LuntSt George$2K
- Douglas AllenPleasant Grove$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.